[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adjuvant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adjuvant":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,73,101,126,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100625035","phase-3-adjuvant-tace-in-hcc-with-high-risk-recurrence-factors-100625035",false,"NCT07417397","Adjuvant TACE in HCC With High-risk Recurrence Factors","The Efficacy and Safety of Adjuvant TACE in Radical Surgery for Hepatocellular Carcinoma With High-risk Recurrence Factors: A Phase III Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 at enrollment;\n* Child-Pugh class A or B7 (score 5-7);\n* having undergone radical hepatic resection at one of the study centers;\n* histopathologically confirmed HCC;\n* undergo hepatic angiography 4-8 weeks after surgery, with confirmation of no intrahepatic tumor staining;\n* have no prior systemic anti-tumor therapy for HCC;\n* have adequate organ and bone marrow function;\n* estimated life expectancy \\>6 months;\n* present with at least one high-risk factor for recurrence (such as tumor rupture; maximum tumor diameter \\>5 cm; multifocal tumors; microvascular invasion on postoperative pathology; Vp1\u002FVp2 portal vein invasion; lymph node metastasis confirmed by postoperative pathology; positive or narrow surgical margin; and Edmondson grade Ⅲ-Ⅳ differentiation).\n\nExclusion Criteria:\n\n* absence of pathological confirmation of HCC;\n* diagnosis of other malignancies within the 5 years prior to enrollment;\n* a history of hepatic encephalopathy, liver transplantation, pleural effusion, ascites, or pericardial effusion with clinical symptoms after curative hepatectomy, as well as a history of drug allergy, active pulmonary tuberculosis, active syphilis infection, autoimmune disease, or long-term glucocorticoid use;\n* participants who have experienced severe infections within 4 weeks before the first dose, or who have previously received systemic anti-tumor therapy;\n* pregnant or lactating women are ineligible for participation;\n* participants who are unable to comply with the treatment regimen or complete the follow-up requirements.","ALL","18 Years","70 Years",{"count":20,"type":21},442,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended as an adjuvant therapy after curative hepatectomy, aiming to reduce postoperative recurrence and ultimately improve overall survival. However, the effectiveness of such adjuvant postoperative therapy remains controversial. In contrast, guidelines from other countries or regions do not recommend adjuvant TACE after curative hepatectomy. This discrepancy may stem from the fact that adjuvant TACE primarily serves to detect intrahepatic residual lesions via digital subtraction angiography, rather than exerting preventive or therapeutic effects through the embolic agents or chemotherapeutic drugs themselves. This study will evaluate the impact of adjuvant TACE on recurrence-free survival in HCC patients with high-risk recurrence factors who have undergone curative hepatectomy. This study is a Phase III randomized controlled trial in which a total of 442 eligible participants will be randomized in a 1:1 ratio to either the adjuvant TACE group or the intensive follow-up group. The two groups will be compared with respect to recurrence-free survival, overall survival, incidence of treatment-related adverse events and serious adverse events, incidence of treatment discontinuation due to treatment-related adverse events or serious adverse events, median recurrence-free survival, and time to recurrence.",[27,28,29],"Hepatocellular Carcinoma","Adjuvant","Transarterial Chemoembolization",[31,32,33],"transarterial chemoembolization","hepatocellular carcinoma","adjuvant","RECRUITING","2026-02-11",{"date":37,"type":38},"2026-02-18","ACTUAL",{"date":40,"type":38},"2026-02-01",{"date":42,"type":21},"2029-12-31",{"name":44,"class":45},"Guangxi Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100603828","fentanyl-versus-ketorolac-as-an-adjuvant-to-peribulbar-block-for-anterior-segment-surgeries-100603828","NCT07141589","Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries","Fentanyl Versus Ketorolac as an Adjuvant to Peribulbar Block for Anterior Segment Surgeries, A Prospective Double-blinded Randomized Controlled Study","Inclusion Criteria:\n\n* Age over 18 years old.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I-III.\n* Scheduled to undergo operations for anterior segment surgeries of the eye under local (peribulbar) anesthesia.\n\nExclusion Criteria:\n\n* Patient's refusal.\n* Known allergy or hypersensitivity to aspirin or nonsteroidal anti-inflammatory medications.\n* Patients with contraindications to local anesthetics, such as high axial length or patients with high preoperative intraocular pressure.\n* If cases develop severe pain intraoperatively from the start, necessitating rescue analgesia and sedation or requiring conversion to general anesthesia.\n* Infection at the site of injection.\n* Patients with coagulopathies or on anticoagulants.\n* Impaired renal function.",{"count":55,"type":21},168,[57],"NA","This study aims to compare the efficacy of ketorolac and fentanyl as adjuvants to local anesthetics for anterior segment surgeries of the eye.",[60,61,28,62,63],"Fentanyl","Ketorolac","Peribulbar Block","Anterior Segment Surgeries","2025-08-19",{"date":66,"type":38},"2025-08-26",{"date":68,"type":38},"2024-08-25",{"date":70,"type":21},"2025-11-25",{"name":72,"class":45},"Cairo University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100603669","dexamethasone-versus-magnesium-sulphate-as-an-adjuvant-to-bupivacaine-in-ultrasound-guided-erector-spinae-plane-block-for-postoperative-analgesia-in-elective-caesarean-section-under-spinal-anesthesia-100603669","NCT07139522","Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia","The Efficacy of Dexamethasone Versus Magnesium Sulphate as an Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Elective Caesarean Section Under Spinal Anesthesia: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Age from 18 to 35 years.\n* Full-term, singleton, pregnant women.\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled for elective cesarean delivery under spinal anesthesia.\n\nExclusion Criteria:\n\n* Refusal of the patient.\n* Emergency caesarean sections.\n* Patients having chronic diseases as asthma, cardiovascular disorders (Significant arrhythmias, Severe Valvular diseases, congenital heart diseases, ischemic heart disease, cardiomyopathy, deep venous thrombosis ,and pulmonary embolism)\n* Renal impairment (Creatinine level ≥ 2mg\u002Fdl, urea ≥ 25mg\u002FdL), liver impairment \\[Alanine aminotransferase (ALT) \\\u003C 45 U\u002FL, Aspartate aminotransferase (AST) \\\u003C 45 U\u002FL\\].\n* Allergy to the drug enrolled in the study.\n* Body mass index (BMI) ≥ 35 kg\u002Fm2.\n* Hypertensive disorders of pregnancy.\n* Contraindication to spinal anesthesia, such as coagulopathy \\[platelet count \\\u003C150.000, international normalized ratio (INR) \\> 1.2\\], or local infection.\n* Requirement for conversion to general anesthesia after spinal anesthesia will also be excluded.","35 Years",{"count":82,"type":21},150,[57],"This study aims to compare the efficacy of adding dexamethasone and magnesium sulfate as an adjuvant to bupivacaine in bilateral erector spinae block in postoperative pain control in patients undergoing caesarean section under spinal anesthesia.",[86,87,28,88,89,90,91,92],"Dexamethasone","Magnesium Sulphate","Ultrasound","Erector Spinae Plane Block","Postoperative Analgesia","Cesarean Section","Spinal Anesthesia","2025-08-18",{"date":95,"type":38},"2025-08-24",{"date":97,"type":38},"2023-12-01",{"date":99,"type":21},"2025-12-01",{"name":72,"class":45},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":122,"leadSponsor":124,"locationsCount":46},"100592476","dexmedetomidine-as-an-adjuvant-to-bupivacaine-in-scalp-block-versus-bupivacaine-alone-for-postoperative-pain-management-in-patients-undergoing-craniotomy-100592476","NCT06993922","Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block Versus Bupivacaine Alone for Postoperative Pain Management in Patients Undergoing Craniotomy","Inclusion Criteria:\n\n* Age from 18 to 65 years.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Undergoing supratentorial elective planned craniotomies.\n\nExclusion Criteria:\n\n* Patients refusal.\n* History of known allergy to the used local anesthetic or dexmedetomidine.\n* Bleeding disorders.\n* Evidence of local infection at the site of injection.\n* Emergency craniotomy.\n* Psychotic disorder.\n* Patients who will not be extubated in the operating room after surgery.","65 Years",{"count":109,"type":21},50,[57],"This study aims to compare dexmedetomidine as an adjuvant to bupivacaine in scalp block versus bupivacaine alone for postoperative pain management in patients undergoing craniotomy.",[113,28,114,115,116,117],"Dexmedetomidine","Bupivacaine","Scalp Block","Postoperative Pain","Craniotomy","2025-05-29",{"date":120,"type":38},"2025-05-30",{"date":118,"type":38},{"date":123,"type":21},"2025-11-01",{"name":125,"class":45},"Ain Shams University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":107,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":46},"100547128","phase-4-efficacy-safety-baidiziyin-shenqiyifei-adjunctive-treatments-pulmonary-tuberculosis-100547128","NCT06403943","Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis","A Randomized, Controlled, Multicenter Clinical Study on the Efficacy and Safety of BaiDiZiYin Pill and ShenQiYiFei Pill as Adjunctive Treatments for Newly Diagnosed Pulmonary Tuberculosis Patients","Inclusion Criteria:\n\n* 1\\. Age: 18 to 65 years old, regardless of gender;\n* 2\\. Meets the diagnostic criteria for Western medicine pulmonary tuberculosis (formulated in accordance with the health industry standard WS 288-2017 \"Diagnosis of Pulmonary Tuberculosis\" of the People's Republic of China \\[9\\])\n* 3\\. Have not received anti tuberculosis treatment in the past, or have received HRZE anti tuberculosis treatment for less than 1 week as a first-line option\n* 4\\. The subjects themselves have informed consent, voluntarily participate in this study, have good medication compliance, and have signed the subject's informed consent form.\n\nConforming to the diagnostic criteria for Qi and Yin deficiency syndrome in traditional Chinese medicine (in accordance with the industry standards of traditional Chinese medicine in the People's Republic of China - Traditional Chinese Medicine Internal Medicine - Diagnosis and Efficacy Criteria for Disease Symptoms ZY\u002FT0011.1-94) Main symptoms: shortness of breath, fatigue, mental fatigue, weak pulse Secondary symptoms: hemoptysis, spontaneous sweating, night sweating, insufficient appetite, bloating, red and tender tongue, thin coating Diagnosis can be made by having two main symptoms and one secondary symptom.\n\nExclusion Criteria:\n\n* 1\\. Patients who received similar traditional Chinese medicine treatment 4 weeks prior to enrollment;\n* 2\\. Patients with drug-resistant and extensively drug-resistant pulmonary tuberculosis;\n* 3\\. Known or suspected to have a history of allergies or serious adverse reactions to the investigational drug and its excipients, or allergic constitution.\n* 4\\. Patients with drug sensitivity indicating the growth of non tuberculosis mycobacteria (more than twice) or clinically diagnosed with non tuberculosis mycobacterial disease or concomitant non tuberculosis mycobacterial disease;\n* 5\\. For patients with recurrent pulmonary tuberculosis, those with bacterial negative pulmonary tuberculosis or those with initial bacterial positive pulmonary tuberculosis who have received anti tuberculosis treatment for more than one week;\n* 6\\. Patients with combined autoimmune diseases, malignant tumors, severe hematological and hematopoietic system diseases, epilepsy, and psychiatric disorders;\n* 7\\. Concomitant severe organic cardiovascular and cerebrovascular diseases (such as congestive heart failure, myocardial infarction, and acute stroke with NYHA heart function grading of III-IV);\n* 8\\. Merge uncontrolled hypertension (blood pressure ≥ 160\u002F100mmHg at enrollment);\n* 9\\. diabetes with poor glycemic control;\n* 10\\. Concomitant severe liver and kidney diseases, or abnormal liver and kidney function tests (ALT, AST ≥ 2.5 times the upper limit of normal, Scr\\>the upper limit of normal);\n* 11\\. Patients with extrapulmonary tuberculosis such as lymph node tuberculosis, intestinal tuberculosis, bone tuberculosis, renal tuberculosis, epididymal tuberculosis, urogenital tuberculosis, nervous system tuberculosis, and tuberculous meningitis;\n* 12\\. Concomitant with other lung diseases, such as lung tumors, cysts, abscesses, interstitial lung disease, silicosis, pneumoconiosis, etc\n* 13\\. Pregnant and lactating women;\n* 14\\. HIV patients; Syphilis antibody positive patients;\n* 15\\. Individuals who have participated in other clinical trials within 15.1 months;\n* 16\\. Those who suspect or have a history of alcohol or drug abuse or a tendency towards drug dependence;\n* 17\\. The researchers believe that patients are not suitable for inclusion in this trial.",{"count":134,"type":21},292,[136],"PHASE4","This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis. To be included in the initial treatment of pulmonary tuberculosis patients, on the basis of standardized Western medicine treatment, BaidiZiyin Pills and ShenqiYifei Pills will be used to evaluate the clinical efficacy and safety of their products.\n\n1. Evaluate the improvement of symptoms in the adjuvant treatment of newly treated pulmonary tuberculosis with BaidiZiyin Pill and ShenqiYifei Pill.\n2. Explore the sputum negative conversion time and sputum negative conversion rate of BaidiZiyin Pill and ShenqiYifei Pill as adjunctive treatments for newly treated pulmonary tuberculosis.\n3. Explore the protective effects of BaidiZiyin Pill and ShenqiYifei Pill on adverse reactions caused by chemotherapy.",[28,139,140],"Treatment","Tuberculosis","2024-05-03",{"date":143,"type":38},"2024-05-08",{"date":145,"type":38},"2023-05-29",{"date":147,"type":21},"2026-12-31",{"name":149,"class":45},"Beijing Chest Hospital",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":46},"100415374","ajuvant-chemotherapy-and-immunotherapy-in-patients-with-esophageal-esophageal--gastric-junction-cancer-100415374","NCT04688801","Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer","Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer With or Without Preoperative Chemotherapy With High Risk for Recurrence (N+ and\u002F or R1)","Inclusion Criteria:\n\nHistologically proven esophageal or EG-junction carcinoma (Siewert I-II). The heart and lung function can tolerate surgery. The cancer is resectable and incurable therapy will be perfomed.\n\nExclusion Criteria:\n\nEG-junction carcinoma (Siewert III). M1 stage according to the current (8th) version of TNMclassification system. The heart and lung function can't tolerate surgery. R2 Resection Status.","25 Years","80 Years",{"count":160,"type":21},200,[57],"Surgery with or without neoadjuvant therapy is usually used as the treatment for resectable esophageal cancer or esophageal- gastric junction cancer. Patients who have a poor response to neoadjuvant therapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence, to continue with the chemotherapy± radiotherapy is often used in these cases. However, the overall survival is still poor. We designed a prospective randomized controlled tial to study whether immunotherapy could be used with chemotherapy after surgery to improve overall survival. The primary endpoint ofthe study is disease free survival, with secondary endpoints of overall survival, safety and toxicity, and quality of life.",[164,165,166,28],"Esophageal Cancer","Gastroesophageal Cancer","Immunotherapy","2022-11-14",{"date":169,"type":38},"2022-11-16",{"date":171,"type":38},"2020-07-01",{"date":173,"type":21},"2027-12-31",{"name":175,"class":45},"The Second Hospital of Shandong University"]